Table 2.
Pathological characteristics of patients
| Characteristic | Total (n 52) | EG (n 30) | LG (n 22) | p value |
|---|---|---|---|---|
| Histology (n), % | 0.151 | |||
| Pancreatic adenocarcinoma | 24 (46.2) | 13 (43.3) | 11 (50.0) | |
| Ampullary cancer | 11 (21.2) | 5 (16.6) | 6 (27.3) | |
| Distal CBD cancer | 6 (11.5) | 3 (10.0) | 3 (13.6) | |
| NET | 3 (5.8) | 3 (10.0) | 0 (0.0) | |
| Metastasis | 1 (1.9) | 1 (3.3) | 0 (0.0) | |
| SPT | 1 (1.9) | 0 (0.0) | 1 (4.5) | |
| IPMN with LGD | 4 (7.7) | 4 (13.3) | 0 (0.0) | |
| Chronic pancreatitis | 1 (1.9) | 0 (0.0) | 1 (4.6) | |
| SCA | 1 (1.9) | 0 (0.0) | 1 (4.6) | |
| Grading* (n),% | 0.229 | |||
| 1 | 6 (13.0) | 3 (12.0) | 3 (14.3) | |
| 2 | 17 (37.0) | 12 (48.0) | 5 (23.8) | |
| 3 | 23 (50.0) | 10 (40.0) | 13 (61.9) | |
| T stage* (n),% | 0.737 | |||
| 1 | 9 (19.6) | 4 (16.0) | 5 (23.8) | |
| 2 | 26 (56.5) | 16 (64.0) | 10 (47.6) | |
| 3 | 10 (21.7) | 4 (16.0) | 6 (28.6) | |
| 4 | 1 (2.2) | 1 (4.0) | 0 (0.0) | |
| N stage* (n),% | 0.956 | |||
| 0 | 23 (50.0) | 12 (48.0) | 11 (52.4) | |
| 1 | 16 (34.8) | 9 (36.0) | 7 (33.3) | |
| 2 | 7 (15.2) | 4 (16.0) | 3 (14.3) | |
| LNs harvested* median (IQR) | 20 (11–27) | 22 (12–28) | 17 (11–27) | 0.269 |
| Radicality* (n),% | 0.684 | |||
| R0 | 40 (86.9) | 21 (84.0) | 19 (90.5) | |
| R1 | 6 (13.1) | 4 (16.0) | 2 (9.5) |
n number, EG early group, LG late group, CBD common bile duct, NET neuroendocrine tumor, SPT solid pseudopapillary tumor, IPMN intraductal papillary mucinous neoplasm, LGD low-grade dysplasia, SCA serous cystadenoma, T tumor, N nodes, LNs lymph nodes
*Calculated on patients with malignant disease (n 46)